EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Screening for Celiac Disease in Childhood: Cost-Effectiveness of Multiple Genetic and Serological Testing Approaches

Jani Mäkinen, Paula Heikkilä, Juha Pajula, Khaoula El Mekkaoui, Ketil Størdal, Katri Lindfors, Jutta E Laiho, Jukka Ranta, Jyri Rökman, Heikki Hyöty, Frank Emmert-Streib, Kalle Kurppa und 2 weitere

Clinical Gastroenterology and Hepatology · 2026-05 · 24 (5) · 1310-1320

DOI: 10.1016/j.cgh.2025.11.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-05. Verfasst von Jani Mäkinen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Celiac Disease Research Center, Tampere University, Tampere, Finland; Tampere Center for Child, Adolescent and Maternal Health Research, Tampere Univ…. Hauptthemen laut MEDLINE: Celiac Disease, Mass Screening, Genetic Testing, Serologic Tests. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sigrid Jusélius Foundation, Research Council of Finland, Horizon 2020 Framework Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Celiac disease is severely underdiagnosed, and many identified patients suffer from a long diagnostic delay. Population-based screening could improve this under-recognition, but its practical implementation remains unclear. We studied the most cost-effective screening strategy for celiac disease in childhood. METHODS: A Markov model using primarily Swedish data was developed for comparing the cost-effectiveness of various scenarios. Key considerations included serological testing across ages 3 to 18 years, single-time vs repeated screening, and preliminary genetic testing to identify the at-risk population. Outcomes of the resulting 272 strategies were compared against a no-screening alternative using the incremental cost-effectiveness ratio. Sensitivity analysis was conducted at a €20,000 willingness to pay threshold to determine key factors influencing the optimal screening age(s) and conditions where repeated screening would be preferred. RESULTS: Untargeted single-time screening was more cost-effective than repeated screening or the combined use of genetic testing in the default scenario. Single-time screening was most cost-effective at age 11 (95% confidence interval, 10-14 years), and repeated screening at ages 4 and 11. Repeated screening was preferred if prevalence of celiac disease at age 12 was ≥5%, diagnosis improved quality of life for asymptomatic patients, screening costs were halved, or a willingness to pay of €50,000 per quality-adjusted life year was adopted. Diagnostic delay was the key factor influencing the optimal screening age(s). CONCLUSIONS: The most cost-effective screening strategy for celiac disease was single-time untargeted serological testing at age 11. The optimal approach is affected by regional factors and may evolve with new evidence. Repeated screening may be preferable for high-risk groups and with high willingness to pay.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Celiac DiseaseMass ScreeningGenetic TestingSerologic TestsHumansCost-Benefit AnalysisChildAdolescentChild, PreschoolSwedenMaleFemaleMarkov Chains

Stichwörter der Autor:innen

Cost-utility AnalysisHealth EconomicsPediatric ScreeningPreventive Health Care

Autor:innen und Institutionen

  • Celiac Disease Research Center, Tampere University, Tampere, Finland; Tampere Center for Child, Adolescent and Maternal Health Research, Tampere University, Tampere, Finland.
  • Tampere Center for Child, Adolescent and Maternal Health Research, Tampere University, Tampere, Finland; Department of Pulmonology, Dermatology, and Allergology, Tampere University Hospital, Tampere, Finland.
  • VTT Technical Research Centre of Finland Ltd., Tampere, Finland.
  • Department of Computer Science, Aalto University, Espoo, Finland; VTT Technical Research Centre of Finland Ltd, Espoo, Finland.
  • Department of Paediatric Research, Faculty of Medicine, University of Oslo, Oslo, Norway; Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.
  • Celiac Disease Research Center, Tampere University, Tampere, Finland.

Förderung

  • Sigrid Jusélius Foundation
  • Research Council of Finland
  • Horizon 2020 Framework Programme
  • Univerzita Karlova v Praze
  • Tampere University Hospital
  • The Paulo Foundation
  • Emil Aaltonen Fundation
  • Childhood Disease Research Fundation

Zitieren

APA

Mäkinen, J., Heikkilä, P., Pajula, J., El Mekkaoui, K., Størdal, K., Lindfors, K., Laiho, J. E., Ranta, J., Rökman, J., Hyöty, H., Emmert-Streib, F., Kurppa, K., Kivelä, L., & HEDIMED Investigator Group (2026). Screening for Celiac Disease in Childhood: Cost-Effectiveness of Multiple Genetic and Serological Testing Approaches. Clinical Gastroenterology and Hepatology, 24(5), 1310-1320. https://doi.org/10.1016/j.cgh.2025.11.030

Vancouver

Mäkinen J, Heikkilä P, Pajula J, El Mekkaoui K, Størdal K, Lindfors K, et al. Screening for Celiac Disease in Childhood: Cost-Effectiveness of Multiple Genetic and Serological Testing Approaches. Clinical Gastroenterology and Hepatology. 2026;24(5):1310-1320. doi:10.1016/j.cgh.2025.11.030

BibTeX
@article{Mkinen2026,
  author = {Mäkinen, Jani and Heikkilä, Paula and Pajula, Juha and El Mekkaoui, Khaoula and Størdal, Ketil and Lindfors, Katri and Laiho, Jutta E and Ranta, Jukka and Rökman, Jyri and Hyöty, Heikki and Emmert-Streib, Frank and Kurppa, Kalle and Kivelä, Laura and HEDIMED Investigator Group, HEDIMED Investigator Group},
  title = {Screening for Celiac Disease in Childhood: Cost-Effectiveness of Multiple Genetic and Serological Testing Approaches},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {5},
  pages = {1310--1320},
  doi = {10.1016/j.cgh.2025.11.030}
}
Kostenlos starten →